Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study) ; volume:19 ; number:1 ; day:11 ; month:4 ; year:2019 ; pages:1-7 ; date:12.2019
BMC cancer ; 19, Heft 1 (11.4.2019), 1-7, 12.2019
- Creator
-
Iguchi, Taro
Tamada, Satoshi
Kato, Minoru
Yasuda, Sayaka
Yamasaki, Takeshi
Nakatani, Tatsuya
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5526-3
- URN
-
urn:nbn:de:101:1-2019042902391217153744
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Iguchi, Taro
- Tamada, Satoshi
- Kato, Minoru
- Yasuda, Sayaka
- Yamasaki, Takeshi
- Nakatani, Tatsuya
- SpringerLink (Online service)
Other Objects (12)
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Approaching personalized medicine: preclinical evaluation of enzalutamide-resistant castration-resistant prostate cancer and mutated forms of the androgen receptor targeted by a new androgen receptor inhibitor
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Approaching personalized medicine: preclinical evaluation of enzalutamide-resistant castration-resistant prostate cancer and mutated forms of the androgen receptor targeted by a new androgen receptor inhibitor
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Approaching personalized medicine: preclinical evaluation of enzalutamide-resistant castration-resistant prostate cancer and mutated forms of the androgen receptor targeted by a new androgen receptor inhibitor
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions